- Participants debated which human tissue would be the highest-impact target for in-vivo regeneration; grey matter was nominated as the most valuable but also the most difficult, while the thymus was suggested as an easier, high-value organoid candidate.  
- Altos Labs (Bezos-/Milner-funded) was discussed as pursuing Yamanaka-factor-based rejuvenation, with the caveat that this approach is expected to carry a high cancer risk.  
- Michael West’s competing approach (AgEx/Lineage) was highlighted as a potentially safer alternative, with links to a 2011 pluripotency patent (US20110143441) and a Longevity Technology article covering the IP grant.  
- The evolutionary mystery of why birds, mammals, snakes, and crocodilians lost robust regenerative capacity was raised; the leading hypothesis offered was that the loss may have been traded off for improved cancer resistance.  
- Historical engineering trivia: a 1950s Sperry promotional film was cited as evidence that closed-loop positional feedback was present from the earliest days of numerical-control machining, achieving ~2.5 µm precision.  
- Mechanical screw machines were noted to remain in widespread use for high-volume, low-cost parts (pipe fittings, pens, RF connectors) despite CNC dominance, because cam-driven systems are cheaper per unit horsepower.  
- BioViva’s current status was briefly reviewed; no new funding rounds were visible, and their partnership with Integrated Health Systems / IBT Pets was mentioned as their apparent clinical path.